Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL Ins35bp variant via inhibition of RNA polymerase II on genomic BCR‐ABL-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL Ins35bp variant via inhibition of RNA polymerase II on genomic BCR‐ABL

Published:2020-06-14 Issue:7 Volume:111 Page:2361-2373
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Yuda Junichiro¹^ORCID,Odawara Jun¹,Minami Mariko¹,Muta Tsuyoshi²,Kohno Kentaro³,Tanimoto Kazuki⁴,Eto Tetsuya⁵,Shima Takahiro¹,Kikushige Yoshikane¹,Kato Koji¹,Takenaka Katsuto¹,Iwasaki Hiromi¹,Minami Yosuke⁶,Ohkawa Yasuyuki⁷,Akashi Koichi¹,Miyamoto Toshihiro¹^ORCID

Affiliation:

1. Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Science Fukuoka Japan

2. Department of Hematology and Oncology Japan Community Health Care Organization Kyushu Hospital Fukuoka Japan

3. Department of Hematology and Clinical Research Institute National Hospital Organization Kyushu Medical Center Fukuoka Japan

4. Department of Haematology and Oncology Japanese Red Cross Society Fukuoka Red Cross Hospital Fukuoka Japan

5. Department of Hematology Hamanomachi Hospital Fukuoka Japan

6. Department of Hematology National Cancer Center Hospital East Kashiwa Japan

7. Department of Advanced Medical Initiatives Kyushu University Fukuoka Japan

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14424

Reference36 articles.

1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

3. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

4. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

5. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors;Hemato;2022-06-13

2. The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML;Reference Module in Biomedical Sciences;2021